OCULAR DISEASE AND EARLY ONSET MYOPIA
Dr Jessica Mountford
Brian King Fellow &
Head of Functional Molecular Vision Group
Lions Eye Institute, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | November 2024
Dr Jessica Mountford received her highly ranked PhD from Monash University, Melbourne, in 2012, in the field of biochemistry and clinical haematology. Her work investigating novel ways to prevent thrombosis, a leading cause of heart attack and stroke, led to a first author publication in Nature Communications.
Following this, Dr Mountford relocated to Perth and went on to complete two post-doctoral appointments at the University of Western Australia, where she began research on the comparative evolution of visual and non-visual opsin across species of vertebrate, from the primitive lamprey to human.
During this period Dr Mountford began researching novel genetic variants associated with myopia development. With Adjunct Research Fellow appointments held at La Trobe University in Melbourne, and the University of Western Australia, Dr Mountford is currently the 6th Brian King Fellow and the Head of the Functional Molecular Vision Group at the Lions Eye Institute in Perth where she researches both the genetic and environmental factors involved in the development of early-onset myopia.
Dr Mountford has successfully established Western Australia’s first and only ocular genetic screening platform using zebrafish and utilises this model to help elucidate some of the complex gene-environment interactions responsible for the development of myopia.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Metabolic phenotyping, lipidomics & bioinformatics in dementia
Dr Luke Whiley is a dementia researcher whose work focuses on understanding how the body’s metabolism, particularly the biology of fats known as lipids, influences our health throughout ageing.
His research explores how the body responds to illness, lifestyle, and environmental stress at a chemical level, and how these responses shape longterm disease risk. Using advanced blood-based measurement technologies, Dr Whiley studies thousands of small molecules at once to build a snapshot of a person’s metabolic health. By combining these measurements with data science approaches, his work identifies biological pathways that become disrupted in disease, providing insight into why some people are more vulnerable to conditions such as dementia.
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
